Posted by Michael Wonder on 28 May 2019
Canadian Biosimilars Forum applauds B.C. Government's landmark decision to enhance adoption of biosimilars and calls on remaining provinces to follow
27 May 2019 - The Canadian Biosimilars Forum today commends the Government of British Columbia for taking a decisive step toward enhancing patient care by implementing well-controlled, one-time transitions of those patients currently using a reference biologic drug to its biosimilar.
Through this policy move, we believe British Columbia (BC) will secure significant savings that could be reinvested in expanding access to existing therapies and accelerating access to new medicines.
"The province's announcement underscores the value biosimilars can provide to patients and their physicians once a reference biologic medicine has lost market exclusivity, and we urge other provinces across the country to follow B.C.'s lead," said Jennifer Chan, a board member of the Forum and Vice President, Policy and External Affairs at Merck Canada.
